161 related articles for article (PubMed ID: 9816077)
1. Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance.
Ishihara A; Yoshida T; Tamaki H; Sakakura T
Clin Cancer Res; 1995 Sep; 1(9):1035-41. PubMed ID: 9816077
[TBL] [Abstract][Full Text] [Related]
2. Co-expression of tenascin and fibronectin in epithelial and stromal cells of benign lesions and ductal carcinomas in the human breast.
Yoshida T; Matsumoto E; Hanamura N; Kalembeyi I; Katsuta K; Ishihara A; Sakakura T
J Pathol; 1997 Aug; 182(4):421-8. PubMed ID: 9306963
[TBL] [Abstract][Full Text] [Related]
3. Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins.
Dandachi N; Hauser-Kronberger C; Moré E; Wiesener B; Hacker GW; Dietze O; Wirl G
J Pathol; 2001 Feb; 193(2):181-9. PubMed ID: 11180164
[TBL] [Abstract][Full Text] [Related]
4. mRNA expression and protein distribution of the unspliced tenascin-C isoform in prostatic adenocarcinoma.
Katenkamp K; Berndt A; Hindermann W; Wunderlich H; Haas KM; Borsi L; Zardi L; Kosmehl H
J Pathol; 2004 Jul; 203(3):771-9. PubMed ID: 15221936
[TBL] [Abstract][Full Text] [Related]
5. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease.
Adams M; Jones JL; Walker RA; Pringle JH; Bell SC
Cancer Res; 2002 Jun; 62(11):3289-97. PubMed ID: 12036947
[TBL] [Abstract][Full Text] [Related]
6. Tenascin-C protein expression and mRNA splice variants in thyroid carcinoma.
Tseleni-Balafouta S; Gakiopoulou H; Fanourakis G; Voutsinas G; Balafoutas D; Patsouris E
Exp Mol Pathol; 2006 Apr; 80(2):177-82. PubMed ID: 16259977
[TBL] [Abstract][Full Text] [Related]
7. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
8. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
Jahkola T; Toivonen T; von Smitten K; Virtanen I; Wasenius VM; Blomqvist C
Br J Cancer; 1999 Apr; 80(1-2):167-74. PubMed ID: 10389993
[TBL] [Abstract][Full Text] [Related]
9. Tenascin-C expression and its prognostic significance in oral and pharyngeal squamous cell carcinoma.
Atula T; Hedström J; Finne P; Leivo I; Markkanen-Leppänen M; Haglund C
Anticancer Res; 2003; 23(3C):3051-6. PubMed ID: 12926160
[TBL] [Abstract][Full Text] [Related]
10. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and protein distribution of the unspliced large tenascin-C isoform in oral squamous cell carcinoma.
Hindermann W; Berndt A; Borsi L; Luo X; Hyckel P; Katenkamp D; Kosmehl H
J Pathol; 1999 Dec; 189(4):475-80. PubMed ID: 10629546
[TBL] [Abstract][Full Text] [Related]
12. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
13. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
14. Tenascin-C patterns and splice variants in actinic keratosis and cutaneous squamous cell carcinoma.
Dang C; Gottschling M; Roewert J; Forschner T; Stockfleth E; Nindl I
Br J Dermatol; 2006 Oct; 155(4):763-70. PubMed ID: 16965426
[TBL] [Abstract][Full Text] [Related]
15. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical localisation of tenascin in invasive ductal carcinoma of the breast.
Tökés AM; Hortoványi E; Csordás G; Kulka J; Mózes G; Hatalyák A; Kádár A
Anticancer Res; 1999; 19(1A):175-9. PubMed ID: 10226540
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer.
Rudland PS; Platt-Higgins A; El-Tanani M; De Silva Rudland S; Barraclough R; Winstanley JH; Howitt R; West CR
Cancer Res; 2002 Jun; 62(12):3417-27. PubMed ID: 12067984
[TBL] [Abstract][Full Text] [Related]
18. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S
Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078
[TBL] [Abstract][Full Text] [Related]
19. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast.
Brown LF; Guidi AJ; Schnitt SJ; Van De Water L; Iruela-Arispe ML; Yeo TK; Tognazzi K; Dvorak HF
Clin Cancer Res; 1999 May; 5(5):1041-56. PubMed ID: 10353737
[TBL] [Abstract][Full Text] [Related]
20. Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer.
Zhang Z; Yamashita H; Toyama T; Yamamoto Y; Kawasoe T; Iwase H
Clin Cancer Res; 2006 Nov; 12(21):6410-4. PubMed ID: 17085653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
